RYAH Group Inc. (CSE: RYAH) Positioned to Impact Palliative Care with AI-Powered Plant-Based Solutions

  • Palliative care focuses on providing end-of-life care for chronically ill patients
  • Preliminary research suggests cannabis relieves pain, appetite loss, anxiety 
  • RYAH is the leader in volume-control technology for plant-based medicine
  • RYAH’s ecosystem includes volume-control devices, medicine-carrying components, and AI-powered applications that capture and track data

With a mission to advance remote-health solutions and analytics-based patient treatments across the world, RYAH Group (CSE: RYAH), the leader in volume-control technology for plant-based medicine, is positioned to address the urgent need for cannabis-based solutions in palliative care.

Palliative care is an emerging healthcare field that focuses on providing solutions that alleviate the suffering of patients with a chronic diagnosis, including cardiovascular disease, cancer, chronic respiratory disease, AIDS, and diabetes. While end-of-life care is not a curative approach, treatments provided to patients focus on improving quality of life and relieving symptoms such as pain, depression, anxiety, and appetite loss. The World Health Organization (“WHO”) states that only 14 percent of approximately 40 million people that need end-of-life care each year receive it (https://ibn.fm/Nt4zU). 

A growing body of research demonstrates that cannabis and cannabinoids help ease symptoms associated with many chronic diseases (https://ibn.fm/tJFnF). While the research is still ongoing, cannabis continues to be a physician-recommended option to alleviate suffering by relieving symptoms such as pain, anxiety, and loss of appetite. Accordingly, evidence suggests that cannabis can replace opioids or be used as a suitable cotreatment to reduce opioid load (https://ibn.fm/AzgTk), with 67 percent of oncologists reporting that medical cannabis was a helpful treatment in conjunction with standard pain management approaches (https://ibn.fm/67QXG). 

RYAH’s ecosystem of IoT products, including its volume-control devices, medicine-carrying components, and mobile applications, can provide a reliable way for researchers and clinicians to develop well-controlled environments to study the use of cannabis for palliative care. Accordingly, the company’s Smart Dry-Herb Dose-Measuring Inhaler is currently being used in one of the most extensive medical studies ever undertaken. Other devices to follow include a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

The development of RYAH’s Data Ecosystem is part of the company’s goal of generating AI-powered models that can provide precision treatments for various diseases, including chronic conditions requiring end-of-life care. Along with delivering volume-controlled devices, RYAH’s technology stack includes QR tracking applications to track product formulations and dosing parameters, as well as mobile applications that can manage volumetric data and provide patient feedback.

RYAH is dedicated to helping doctors and patients unlock the power of data to provide better patient outcomes. With its robust intellectual property portfolio, AI-powered technology, and suite of portable, cost-effective products, the company is positioned to capitalize on growth opportunities in the IoT and data intelligence sectors while providing critical volume-control solutions for the plant-based medical industry.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

 

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050